Literature DB >> 3101590

In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens.

L D Liebowitz, J Saunders, G Fehler, R C Ballard, H J Koornhof.   

Abstract

The in vitro activities of two new carboxyquinolones, A-56619 (difloxacin) and A-56620, were compared with those of ciprofloxacin, norfloxacin, and ofloxacin against genital tract pathogens. All the quinolones were highly active against Neisseria gonorrhoeae. A-56619 had the lowest MICs against Chlamydia trachomatis (MIC range, 0.125 to 0.25 micrograms/ml) and Haemophilus ducreyi (MIC for 90% of isolates tested, 0.1 micrograms/ml).

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3101590      PMCID： PMC180627          DOI： 10.1128/AAC.30.6.948

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  In vitro activity of norfloxacin against Mycoplasma hominis and Ureaplasma urealyticum.

Authors:  C Simon; U Lindner
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

2.  Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.

Authors:  M Y Khan; Y Siddiqui; R P Gruninger
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

3.  Antimicrobial susceptibility of 103 strains of Haemophilus ducreyi isolated in Johannesburg.

Authors:  Y R Bilgeri; R C Ballard; M O Duncan; A C Mauff; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

4.  Mycoplasmas of various hosts and their antibiotic sensitivities.

Authors:  D Taylor-Robinson
Journal:  Postgrad Med J       Date:  1967-03       Impact factor: 2.401

5.  Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence.

Authors:  J M Bailey; C Heppleston; S J Richmond
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

6.  Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.

Authors:  H H Gadebusch; D L Shungu; E Weinberg; S K Chung
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

7.  Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin.

Authors:  S R Crider; S D Colby; L K Miller; W O Harrison; S B Kerbs; S W Berg
Journal:  N Engl J Med       Date:  1984-07-19       Impact factor: 91.245

8.  In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.

Authors:  F W Heessen; H L Muytjens
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  The antimicrobial susceptibility of Chlamydia trachomatis in cell culture.

Authors:  G L Ridgway; J M Owen; J D Oriel
Journal:  Br J Vener Dis       Date:  1978-04

10.  Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses.

Authors:  T A Tartaglione; A C Raffalovich; W J Poynor; A Espinel-Ingroff; T M Kerkering
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191
View more
  8 in total

1.  In vitro activities of temafloxacin (A-62254) and four other antibiotics against Chlamydia trachomatis.

Authors:  J Segreti; H A Kessler; K S Kapell; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

2.  In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.

Authors:  H Maeda; A Fujii; K Nakata; S Arakawa; S Kamidono
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

3.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

4.  Evaluation of difloxacin in the treatment of uncomplicated urethral gonorrhea in men.

Authors:  B L Smith; M Cummings; S Benes; K Draft; W M McCormack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

5.  In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors:  K B Waites; L B Duffy; T Schmid; D Crabb; M S Pate; G H Cassell
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

6.  In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis.

Authors:  A Nagayama; T Nakao; H Taen
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

Review 7.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 8.  Gardnerella vaginalis: characteristics, clinical considerations, and controversies.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.